Login / Signup

Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease.

Hiroya TamaiYasushi KondoTsutomu TakeuchiYuko Kaneko
Published in: Rheumatology (Oxford, England) (2024)
The recurrence rate after tocilizumab discontinuation was 50% in 1 year. Patients who remained in remission with a longer interval of tocilizumab administration and lower prednisolone dose were likely to succeed in the withdrawal of tocilizumab.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • rheumatoid arthritis patients
  • juvenile idiopathic arthritis
  • systemic lupus erythematosus
  • ulcerative colitis
  • free survival